A combination Revolution
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Targeted lung cancer niche sees a German pharma battle
But could toxicity be holding back filing plans?
BioNTech puts a ring on Biotheus
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
Next for Trodelvy: small-cell lung cancer
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
